Floatz logo

Epirubicin

NK-Cell Lymphoma

The University of Hong KongPhase 2Dormant
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
95/ 100

Competitive context

10 Active assets in the NK-Cell Lymphoma cohort.

Asset / SponsorPhaseRating
Cyclophosphamide
New York Medical College
Phase 3BBB
DEXAMETHASONE
National Cancer Institute (NCI)
Phase 1CCC
Pembrolizumab
The University of Hong Kong
Phase 2CCC
METHOTREXATE
New York Medical College
Early Phase 1C
Ifosfamide
New York Medical College
Early Phase 1C

View all 11 →

Same molecule, other indications

Epirubicin is also rated in:

Recurrent Breast CarcinomaDormant
BBB
Indicative ·
74 / 100
View asset →
Lung Non-Small Cell Squamous CarcinomaDormant
BBB
Indicative ·
72 / 100
View asset →
Advanced/Metastatic Gastroesophageal AdenocarcinomaDormant
BBB
Indicative ·
72 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →